SVRA

Over the past six months, the FDA extended its review period for MOLBREEVI's Biologics License Application (BLA) by three months to November 22, 2026, due to a major amendment. Savara reported a wider net loss of $40.2 million in its second-quarter 2026 financial results, reflecting investments in commercial infrastructure. The company announced encore presentations of positive results from the Phase 3 IMPALA-2 clinical trial of molgramostim at the European Respiratory Society (ERS) Congress in September 2026, following earlier presentations of exercise-capacity and biomarker data. In July 2026, European and Australian patent offices granted patents for the liquid formulation of MOLBREEVI, extending protection until March 2041. Savara also announced new employment inducement grants in June and August 2026. The stock experienced a modest pullback, declining approximately 7.5% over the 30 days leading up to October 10, 2026, with technical indicators suggesting a potential downward trend.